Collegium Pharmaceutical Beheer

Beheer criteriumcontroles 2/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Vikram Karnani

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	no data
Eigendom CEO	n/a
Management gemiddelde ambtstermijn	4.3yrs
Gemiddelde ambtstermijn bestuur	10.8yrs

Recente managementupdates

Recent updates

CEO

Vikram Karnani (49 yo)

no data

Tenure

Mr. Vikram Karnani is CEO & President of Collegium Pharmaceutical, Inc. since November 12, 2024. Mr. Karnani is a Executive Vice President and President, Global Commercial Operations and Medical Affairs (R...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Michael Heffernan	Co-Founder & Chairman	21.1yrs	US$330.61k	0.087% € 804.4k
Colleen Tupper	Executive VP & CFO	3.5yrs	US$2.73m	0.061% € 565.9k
Shirley Kuhlmann	Executive VP	6.7yrs	US$2.87m	0% € 0
Scott Dreyer	Executive VP & Chief Commercial Officer	6.3yrs	US$2.61m	0% € 0
Thomas Smith	Executive VP & Chief Medical Officer	2.7yrs	US$2.04m	0% € 0
Vikram Karnani	CEO & President	no data	geen gegevens	geen gegevens
Christopher James	Vice President of Investor Relations	no data	geen gegevens	geen gegevens
Bart Dunn	Executive Vice President of Strategy & Corporate Development	5.2yrs	geen gegevens	geen gegevens
Scott Sudduth	Head of Technical Operations	3.1yrs	geen gegevens	geen gegevens

4.3yrs

Gemiddelde duur

50.5yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van 354 wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.3 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Michael Heffernan	Co-Founder & Chairman	21.1yrs	US$330.61k	0.087% € 804.4k
John Freund	Independent Director	10.8yrs	US$298.61k	0.22% € 2.0m
Garen Bohlin	Independent Director	9.8yrs	US$299.61k	0.0073% € 67.6k
Gino Santini	Lead Independent Director	12.3yrs	US$322.61k	0.079% € 730.4k
Bill McCarberg	Scientific Advisor	no data	geen gegevens	geen gegevens
Nathaniel Katz	Scientific Advisor	no data	geen gegevens	geen gegevens
Robert Dworkin	Scientific Advisor	no data	geen gegevens	geen gegevens
Lynn Webster	Scientific Advisor	no data	geen gegevens	geen gegevens
John Fallon	Independent Director	8.4yrs	US$289.61k	0.12% € 1.1m
Cynthia McCormick	Scientific Advisor	no data	geen gegevens	geen gegevens
Richard Rauck	Scientific Advisor	no data	geen gegevens	geen gegevens
Charles Argoff	Scientific Advisor	no data	geen gegevens	geen gegevens

10.8yrs

Gemiddelde duur

70yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 354 zijn ervaren en ervaren (gemiddelde ambtstermijn van 10.8 jaar).

Collegium Pharmaceutical Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

Collegium Pharmaceutical, Inc. Announces Executive Changes, Effective November 12, 2024

Executive VP & Chief Medical Officer recently sold €317k worth of stock

Executive VP recently sold €697k worth of stock

Executive VP & Chief Commercial Officer recently sold €1.0m worth of stock

Collegium Announces CEO Transition

Collegium Pharmaceutical, Inc., Annual General Meeting, May 16, 2024

Recent updates

Third quarter 2024 earnings released: EPS: US$0.29 (vs US$0.61 in 3Q 2023)

Collegium Pharmaceutical, Inc. Announces Executive Changes, Effective November 12, 2024

Collegium Pharmaceutical, Inc. to Report Q3, 2024 Results on Nov 07, 2024

Executive VP & Chief Medical Officer recently sold €317k worth of stock

Executive VP recently sold €697k worth of stock

Collegium Pharmaceutical, Inc. Updates Financial Guidance for the Full Year 2024

Second quarter 2024 earnings released: EPS: US$0.60 (vs US$0.38 in 2Q 2023)

New minor risk - Share price stability

Investor sentiment improves as stock rises 18%

Collegium Pharmaceutical, Inc. Provides Net Product Revenues Guidance for the Second Quarter Ended June 30, 2024; Reaffirms Financial Guidance for the Full Year 2024

Collegium Pharmaceutical, Inc. (NasdaqGS:COLL) agreed to acquire Ironshore Therapeutics Inc. for approximately CAD 550 million.

Collegium Pharmaceutical, Inc. to Report Q2, 2024 Results on Aug 08, 2024

Executive VP & Chief Commercial Officer recently sold €1.0m worth of stock

Collegium Pharmaceutical, Inc. Reaffirms Earnings Guidance for the Full Year 2024

First quarter 2024 earnings released: EPS: US$0.86 (vs US$0.51 loss in 1Q 2023)

Collegium Announces CEO Transition

Collegium Pharmaceutical, Inc. to Report Q1, 2024 Results on May 09, 2024

Collegium Pharmaceutical, Inc., Annual General Meeting, May 16, 2024

Investor sentiment improves as stock rises 17%

Full year 2023 earnings released: EPS: US$1.43 (vs US$0.74 loss in FY 2022)

Collegium Pharmaceutical, Inc. to Report Q4, 2023 Results on Feb 22, 2024

Collegium Pharmaceutical, Inc. Revises Earnings Guidance for the Full-Year of 2023

Collegium Pharmaceutical, Inc. Revises Earnings Guidance for the Full-Year of 2023

New major risk - Financial position

New minor risk - Shareholder dilution

Collegium Pharmaceutical, Inc. to Report Q3, 2023 Results on Nov 07, 2023

Collegium Pharmaceutical, Inc. Announces Extension of Nucynta Regulatory Exclusivity Through July 2026

Second quarter 2023 earnings released: EPS: US$0.38 (vs US$0.15 loss in 2Q 2022)

Collegium Pharmaceutical, Inc. Reaffirms Earnings Guidance for the Year 2023

Collegium Pharmaceutical, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Collegium Pharmaceutical, Inc. Reaffirms Product Revenues Guidance for Full-Year 2023

First quarter 2023 earnings released: US$0.51 loss per share (vs US$0.39 loss in 1Q 2022)

Full year 2022 earnings released: US$0.74 loss per share (vs US$2.05 profit in FY 2021)

Collegium Pharmaceutical, Inc. to Report Q4, 2022 Results on Feb 23, 2023

Collegium Pharmaceutical, Inc. Provides Earnings Guidance for the Year of 2023

Appeals Court Affirms Validity of Collegium's Belbuca(R) Patents

Insufficient new directors

Collegium Pharmaceutical, Inc. Provides Earnings Guidance for the Year of 2022

Third quarter 2022 earnings released: EPS: US$0.013 (vs US$0.23 in 3Q 2021)

Collegium Pharmaceutical, Inc. to Report Q3, 2022 Results on Nov 03, 2022

Second quarter 2022 earnings released: US$0.15 loss per share (vs US$2.06 profit in 2Q 2021)

Collegium Pharmaceutical, Inc. to Report Q2, 2022 Results on Aug 04, 2022

Investor sentiment improved over the past week

First quarter 2022 earnings released: US$0.39 loss per share (vs US$0.45 profit in 1Q 2021)

Insufficient new directors

Collegium Pharmaceutical, Inc. Appoints Neil McFarlane to its Board of Directors

Collegium Pharmaceutical, Inc. Provides Revenue Guidance for the Year 2022

Collegium Pharmaceutical, Inc. Announces Master Settlement Agreement Resolving Pending Opioid-Related Litigation

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Collegium Pharmaceutical, Inc. Provides Earnings Guidance for the Year 2022

Investor sentiment improved over the past week

Collegium Pharmaceutical, Inc. (NasdaqGS:COLL) entered into an agreement to acquire BioDelivery Sciences International, Inc. (NasdaqGS:BDSI) for approximately $580 million.

Collegium Pharmaceutical, Inc. (NasdaqGS:COLL) entered into an agreement to acquire BioDelivery Sciences International, Inc. (NasdaqGS:BDSI) for approximately $580 million.

Collegium Pharmaceutical, Inc. Announces Settlement Framework to Resolve All 27 Pending Opioid-Related Litigation

Third quarter 2021 earnings released: EPS US$0.23 (vs US$0.33 in 3Q 2020)

Executive VP & Chief Technical Officer Alison Fleming has left the company

Collegium Pharmaceutical, Inc. (NasdaqGS:COLL) announces an Equity Buyback for $100 million worth of its shares.

Second quarter 2021 earnings released: EPS US$2.06 (vs US$0.23 in 2Q 2020)

Collegium Pharmaceutical, Inc. Provides Revenue Guidance for the Full Year 2021

Investor sentiment deteriorated over the past week

Executive VP & CFO has left the company

First quarter 2021 earnings released: EPS US$0.45 (vs US$0.013 in 1Q 2020)

Investor sentiment deteriorated over the past week

Full year 2020 earnings released: EPS US$0.78 (vs US$0.68 loss in FY 2019)

Revenue misses expectations

New 90-day high: €21.20

Investor sentiment improved over the past week

New 90-day high: €20.00